Vertex [VRTX] vs Revolution Medicines [RVMD] Detailed Stock Comparison

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

Revolution Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Vertex Pharmaceuticals Inc. wins in 15 metrics, Revolution Medicines Inc. wins in 1 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Vertex Pharmaceuticals Inc. Revolution Medicines Inc. Better
P/E Ratio (TTM) 28.40 -22.73 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 5.92 16.24 Vertex Pharmaceuticals Inc.
Debt-to-Equity Ratio 10.91 26.19 Vertex Pharmaceuticals Inc.
PEG Ratio 0.88 -0.34 Vertex Pharmaceuticals Inc.
EV/EBITDA 21.78 -21.33 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 32.94% 0.00% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 39.60% 0.00% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) 39.60% N/A N/A
Return on Equity 22.54% -58.07% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) 12.16% -30.08% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $3.19B $-913.73M Vertex Pharmaceuticals Inc.
1-Year Return -2.31% 279.08% Revolution Medicines Inc.
Price-to-Sales Ratio (TTM) 9.22 N/A N/A
Enterprise Value $105.96B $25.05B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 8.83 N/A N/A
Gross Profit Margin (TTM) 85.39% N/A N/A
Revenue per Share (TTM) $47 $0 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $15.32 $-5.95 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.37 1.01 Vertex Pharmaceuticals Inc.
Short % of Float 1.78% 8.24% Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. vs Revolution Medicines Inc. Stock Performance Analysis

Loading Price Chart...

VRTX
RVMD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Vertex Pharmaceuticals Inc.1.24%1.69%3.09%-3.36%-1.15%-0.37%
Revolution Medicines Inc.4.02%7.79%9.89%61.68%102.61%102.56%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Vertex Pharmaceuticals Inc.-2.31%27.89%136.85%413.01%888.51%1,245.83%
Revolution Medicines Inc.279.08%524.98%353.09%443.52%443.52%443.52%

Performance & Financial Health Analysis: Vertex Pharmaceuticals Inc. vs Revolution Medicines Inc.

MetricVRTXRVMD
Market Information
Market Cap i$109.45B$28.61B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i1,057,0616,162,984
90 Day Avg. Volume i1,272,0973,260,005
Last Close$450.46$160.06
52 Week Range$362.50 - $507.92$34.00 - $166.50
% from 52W High-11.31%-3.87%
All-Time High$519.88 (Nov 04, 2024)$166.50 (Jun 01, 2026)
% from All-Time High-13.35%-3.87%
Growth Metrics
Quarterly Revenue Growth0.10%N/A
Quarterly Earnings Growth0.31%N/A
Financial Health
Profit Margin (TTM) i0.33%0.00%
Operating Margin (TTM) i0.40%0.00%
Return on Equity (TTM) i0.23%-0.58%
Debt to Equity (MRQ) i10.9126.19
Cash & Liquidity
Book Value per Share (MRQ)$73.49$8.28
Cash per Share (MRQ)$26.01$10.22
Operating Cash Flow (TTM) i$3.63B$-897,740,992
Levered Free Cash Flow (TTM) i$2.57B$-523,279,008
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Vertex Pharmaceuticals Inc. vs Revolution Medicines Inc.

MetricVRTX (Apr 26, 2026)RVMD (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i28.40-22.73
Forward P/E i19.95-25.66
PEG Ratio i0.88-0.34
Price to Sales (TTM) i9.22N/A
Price to Book (MRQ) i5.9216.24
Market Capitalization
Market Capitalization i$109.45B$28.61B
Enterprise Value i$105.96B$25.05B
Enterprise Value Metrics
Enterprise to Revenue i8.83N/A
Enterprise to EBITDA i21.78-21.33
Risk & Other Metrics
Beta i0.371.01
Book Value per Share (MRQ) i$73.49$8.28

Financial Statements Comparison: Vertex Pharmaceuticals Inc. vs Revolution Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricVRTX (2025)RVMD (2025)
Revenue/Sales i12.00B0
Cost of Goods Sold i1.65BN/A
COGS % of Revenue i13.8%-
Gross Profit i10.35BN/A
Gross Margin i86.2%-
Research & Development i4.04B987.33M
Operating Income (EBIT) i4.55B-1.18B
Operating Margin i37.9%-
EBITDA i5.25B-1.08B
EBITDA Margin i43.7%-
Pre-Tax Income i4.64B-1.13B
Pre-Tax Income % of Revenue i38.7%-
Income Tax i690.00M0
Income Tax % of Revenue i5.7%-
Net Income (Profit) i3.95B-1.13B
Profit Margin i32.9%-

Balance Sheet & Liquidity Metrics

MetricVRTX (2025)RVMD (2025)
Cash & Equivalents i5.08B383.75M
Total Current Assets i11.20B2.08B
Total Current Assets % of Revenue i93.3%-
Total Current Liabilities i3.86B290.42M
Total Current Liabilities % of Revenue i32.2%-
Long-Term Debt i1.95B142.23M
Long-Term Debt % of Revenue i16.3%-
Total Shareholders Equity i18.67B1.63B
Retained Earnings i13.56B-2.87B
Retained Earnings % of Revenue i113.0%-
Property, Plant & Equipment i1.56B162.18M

Cash Flow Statement Comparison

MetricVRTX (2025)RVMD (2025)
Operating Cash Flow i3.77B-975.88M
Operating Cash Flow % of Revenue i31.4%-
Capital Expenditures i-437.60M-15.99M
Free Cash Flow i3.19B-913.73M
FCF Margin i26.6%-
Debt Repayment i-5.40MN/A
Common Stock Repurchase i-2.39BN/A

Short Interest & Institutional Ownership Analysis

MetricVRTXRVMD
Shares Short i4.02M15.41M
Short Ratio i2.807.98
Short % of Float i1.78%8.24%
Shares Outstanding i253.99M197.00M
Float Shares i253.24M179.91M
% Held by Insiders i0.21%1.83%
% Held by Institutions i97.60%95.78%
% Held by Public i2.19%2.39%

Dividend Analysis & Yield Comparison: Vertex Pharmaceuticals Inc. vs Revolution Medicines Inc.

MetricVRTXRVMD
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A